title: Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.
abstract: Recent reports have linked the expression of specific microRNAs (miRNAs) with tumorigenesis and metastasis. Here, we show that microRNA (miR)-16, which is expressed at lower levels in prostate cancer cells, affects the proliferation of human prostate cancer cell lines both in vitro and in vivo. Transient transfection with synthetic miR-16 significantly reduced cell proliferation of 22Rv1, Du145, PPC-1, and PC-3M-luc cells. A prostate cancer xenograft model revealed that atelocollagen could efficiently deliver synthetic miR-16 to tumor cells on bone tissues in mice when injected into tail veins. In the therapeutic bone metastasis model, injection of miR-16 with atelocollagen via tail vein significantly inhibited the growth of prostate tumors in bone. Cell model studies indicate that miR-16 likely suppresses prostate tumor growth by regulating the expression of genes such as CDK1 and CDK2 associated with cell-cycle control and cellular proliferation. There is a trend toward lower miR-16 expression in human prostate tumors versus normal prostate tissues. Thus, this study indicates the therapeutic potential of miRNA in an animal model of cancer metastasis with systemic miRNA injection and suggest that systemic delivery of miR-16 could be used to treat patients with advanced prostate cancer.
authors.affiliation: Section for Studies on Metastasis, National Cancer Center Research Institute, Tokyo, Japan.
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Takeshita
authors.forename: Lubna
authors.initials: L
authors.lastname: Patrawala
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Osaki
authors.forename: Ryou-u
authors.initials: RU
authors.lastname: Takahashi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Kosaka
authors.forename: Masaki
authors.initials: M
authors.lastname: Kawamata
authors.forename: Kevin
authors.initials: K
authors.lastname: Kelnar
authors.forename: Andreas G
authors.initials: AG
authors.lastname: Bader
authors.forename: David
authors.initials: D
authors.lastname: Brown
authors.forename: Takahiro
authors.initials: T
authors.lastname: Ochiya
mesh_terms: D000368:Aged; D000818:Animals; D018797:Cell Cycle Proteins / Q000235:genetics / Q000502:physiology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D035683:MicroRNAs / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000627:therapeutic use*; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D018797:Cell Cycle Proteins; D035683:MicroRNAs